Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
MD Anderson leads the way in combining microbiome insights with cancer therapy, revealing how dietary interventions can transform patient outcomes and advance precision medicine.
The progression of chronic kidney disease can take patients and doctors by surprise. But if public awareness about the risks of this potential killer changes, the prognosis for patients could too.
Targeting IL-17 signalling as a cancer therapy can trigger an imbalance in gut microbiota that fuels tumour growth, but the right antibiotics could break this damaging feedback loop.
As the science behind a novel approach to treating disease evolves, the focus of research and clinical development is expanding from rare conditions to far more common diseases.
With the life science park as the jewel in its crown, the life sciences zone in the Changping district of Beijing is growing and branching out into novel areas of research and development.
How can we unleash the potential of AI while managing the risks? Do we need to restrict powerful AIs to vetted experts? Global experts convened in Hong Kong to plot a safe future for AI.
Laboratory assessments — from preclinical research through post-marketing surveillance — determine whether a cell-based therapy for cancer succeeds or fails.
Hundreds of early- and mid-career scientists from around the world gathered in China for an exchange of ideas in late 2023. new research awards for sustainable development were a notable focus.
By bringing together scientists with a broad range of expertise, a high-risk, high-reward programme is seeking to deliver fault-tolerant quantum computers by 2050.